HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
RecruitingNCT05957848

Guanfacine extended-release or placebo for cannabis use in adolescents

About this titleRead the official source — NCT05957848
Medication studyAges 12–25AustraliaAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 12 years to 25 years.

What will I do during this study?

Participants are randomly assigned to take extended-release guanfacine or a placebo (an inactive comparison treatment) once a day for about 12 weeks. Both groups continue to receive usual care. The study measures cannabis use weekly during the four weeks after participants leave residential withdrawal care.

Listed locations
ParkvilleSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 27, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
100
Sponsor
Orygen
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Behavioural, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Australia
Age range
From 12 Years to 25 Years
Official registry ID
NCT05957848
Official title
Show the full official title

Guanfacine Extended-release Randomised Controlled Trial for Adolescents With Cannabis usE (GRACE)

Recruitment & locations

Currently recruiting

Parkville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Orygen.

Does this study involve medication?

Yes. The study involves medication, including Guanfacine Extended Release Oral Tablet and Placebo.

Who can participate?

Listed age limits: 12 years to 25 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies